Investigational drug · Phase 3
WX390
Also called: WXFL10030390
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Cervical Cancer Metastatic, Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "WX390"
First trial start
2022
Nov 18, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WX390", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
- Cervical Cancer Metastatic
- Solid Tumor
Approved drugs for the same conditions: Stomach and esophageal cancer · Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "WX390" as an intervention, largest first.
- A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based TreatmentPivotal-lookingNot yet recruiting
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT07392060 · 440 participants (planned) · Start Feb 28, 2026 · Primary completion Sep 30, 2029
Drug: WX390 1.1mg + Toripalimab 240mg; Investigator's Choice of Chemotherapy · For: Cervical Cancer Metastatic
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT06117566 · 100 participants (planned) · Start Nov 18, 2022 · Primary completion Nov 9, 2025
Drug: WX390; Toripalimab · For: Solid Tumor
Sites: Changchun, China
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT03730142 · 82 participants · Start Oct 25, 2018 · Primary completion Jul 25, 2020
Drug: WXFL10030390 · For: Advanced Cancer
Sites: Shanghai, China
- A Study of WX390 in Patients With Advanced Solid TumorsStatus unknown
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT06117540 · 70 participants (planned) · Start May 11, 2021 · Primary completion Jun 12, 2025
Drug: WX390 · For: Solid Tumor
Sites: Shanghai, China
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT06132932 · 38 participants · Start Jun 3, 2021 · Primary completion Jan 3, 2023
Drug: WX390 · For: PIK3CA Mutation-Related Tumors
Sites: Shanghai, China
Shanghai Jiatan Pharmatech Co., LtdIndustry
NCT06124963 · 20 participants (planned) · Start Aug 25, 2023 · Primary completion Dec 12, 2025
Drug: WX390; Toripalimab · For: Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- In Vivo PK-PD and Drug-Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia.
Jin G, Zheng K, Liu S, et al. · Pharmaceuticals (Basel) 2025
- PIK3CA inhibitor treatment for metastatic scrotal extramammary Paget's disease: a case report and literature review.
Huang Y, Dong S, Ren J, et al. · AME Case Rep 2025
- Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.
Zheng K, Jin G, Cao R, et al. · Cancer Chemother Pharmacol 2025
- PIK3CA mutations enhance the adipogenesis of ADSCs in facial infiltrating lipomatosis through TRPV1.
Chen H, Sun B, Gao W, et al. · iScience 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.